Association between initiation of antiretroviral therapy 25-hydroxyvitamin D

Antiviral Therapy 15, 425-429

DOI: 10.3851/imp1502

Citation Report

#	Article	IF	CITATIONS
1	Micronutrients and HIV infection. HIV Therapy, 2010, 4, 437-469.	0.6	10
2	Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. Aids, 2010, 24, 2679-2686.	1.0	82
3	HIV and Bone Loss. Current Osteoporosis Reports, 2010, 8, 219-226.	1.5	27
4	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. Journal of the International AIDS Society, 2010, 13, O43.	1.2	2
5	Improvement in Vitamin D Deficiency Following Antiretroviral Regime Change: Results from the MONET Trial. AIDS Research and Human Retroviruses, 2011, 27, 29-34.	0.5	85
6	Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Journal of Hepatology, 2011, 55, 756-761.	1.8	89
7	Future Perspectives in NNRTI-Based Therapy: Bases for Understanding Their Toxicity. , $2011, \ldots$		1
8	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. Aids, 2011, 25, 1305-1315.	1.0	157
9	Do nevirapine and efavirenz affect vitamin D homeostasis similarly?. Aids, 2011, 25, 875-876.	1.0	9
10	Assessment and modification of cardiovascular disease risk in the HIV-infected individual. Future Virology, 2011, 6, 307-320.	0.9	2
11	Bone Turnover, Osteoprotegerin/Rankl and Inflammation with Antiretroviral Initiation: Tenofovir versus Non-Tenofovir Regimens. Antiviral Therapy, 2011, 16, 1063-1072.	0.6	78
12	Vitamin D is Linked to Carotid Intima-Media Thickness and Immune Reconstitution in HIV-Positive Individuals. Antiviral Therapy, 2011, 16, 555-563.	0.6	75
13	Vitamin D Supplementation and Endothelial Function in Vitamin D Deficient HIV-Infected Patients: A Randomized Placebo-Controlled Trial. Antiviral Therapy, 2012, 17, 613-621.	0.6	89
14	Vitamin D Supplementation and CD4 Count in Children Infected with Human Immunodeficiency Virus. Journal of Pediatrics, 2011, 159, 951-957.	0.9	53
15	Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporosis International, 2011, 22, 477-487.	1.3	43
16	Vitamin D in HIV-Infected Patients. Current HIV/AIDS Reports, 2011, 8, 133-141.	1.1	70
17	The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations. Current Infectious Disease Reports, 2011, 13, 83-93.	1.3	31
18	Os, infection par le VIH et antirétroviraux. Revue Du Rhumatisme Monographies, 2011, 78, 101-106.	0.0	2

#	Article	IF	Citations
19	Increasing Clarity on Bone Loss Associated With Antiretroviral Initiation. Journal of Infectious Diseases, 2011, 203, 1705-1707.	1.9	21
20	Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. Journal of Infectious Diseases. 2011. 203. 1791-1801.	1.9	435
21	The Effect of Antiretrovirals on Vitamin D. Clinical Infectious Diseases, 2011, 52, 406-408.	2.9	23
22	Diabetes mellitus, HIV infection, and vitamin D: time to act or time to think?. Aids, 2011, 25, 531-533.	1.0	3
23	Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use?. Aids, 2011, 25, 873-874.	1.0	22
24	Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Women in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 197-204.	0.9	97
25	HIV and its effects on bone. Current Opinion in Rheumatology, 2012, 24, 567-575.	2.0	11
26	Serum 25-Hydroxyvitamin D Response to Vitamin D ₃ Supplementation 50,000 IU Monthly in Youth with HIV-1 Infection. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4004-4013.	1.8	45
27	High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. Journal of Antimicrobial Chemotherapy, 2012, 67, 2222-2230.	1.3	72
28	Hyperparathyroidism and Complications Associated with Vitamin D Deficiency in HIV-Infected Adults in New York City, New York. AIDS Research and Human Retroviruses, 2012, 28, 1025-1032.	0.5	23
29	Review of Metabolic, Immunologic, and Virologic Consequences of Suboptimal Vitamin D Levels in HIV Infection. AIDS Patient Care and STDs, 2012, 26, 516-525.	1.1	16
30	Bone Loss in the HIV-Infected Patient: Evidence, Clinical Implications, and Treatment Strategies. Journal of Infectious Diseases, 2012, 205, S391-S398.	1.9	103
31	Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 161-169.	0.9	24
32	Rilpivirine in the treatment of HIV infection: evidence from the ECHO and THRIVE studies. Clinical Investigation, 2012, 2, 1133-1144.	0.0	1
33	Incidence of low and high-energy fractures in persons with and without HIV infection. Aids, 2012, 26, 285-293.	1.0	134
34	Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. Aids, 2012, 26, 253-262.	1.0	50
35	Risk Factors for Vitamin D Deficiency and Relationship with Cardiac Biomarkers, Inflammation and Immune Restoration in HIV-Infected Youth. Antiviral Therapy, 2012, 17, 1069-1078.	0.6	33
36	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. Future Virology, 2012, 7, 1127-1134.	0.9	3

#	Article	IF	Citations
37	Prevalence of Vitamin D Deficiency and Its Related Risk Factor in a Spanish Cohort of Adult HIV-Infected Patients: Effects of Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2012, 28, 963-971.	0.5	46
38	Complications resulting from antiretroviral therapy for HIV infection. , 2012, , 177-191.		0
39	HIV Infection and Osteoporosis: Pathophysiology, Diagnosis, and Treatment Options. Current Osteoporosis Reports, 2012, 10, 270-277.	1.5	21
40	The Role of Vitamin D Deficiency in the Pathogenesis of Osteoporosis and in the Modulation of the Immune System in HIV-Infected Patients. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 277-287.	1.3	7
41	Osteopenia, Osteoporosis, and Fractures in HIV-Infected Patients: Extent of the Problem. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 246-256.	1.3	1
42	Molecular Bases of Osteoporosis in HIV: The Role of the Virus and Antiretroviral Therapy. Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 236-245.	1.3	0
43	Reduced Quantitative Ultrasound Bone Mineral Density in HIV-Infected Patients on Antiretroviral Therapy in Senegal. PLoS ONE, 2012, 7, e31726.	1.1	19
44	Vitamin D and HIV Progression among Tanzanian Adults Initiating Antiretroviral Therapy. PLoS ONE, 2012, 7, e40036.	1.1	55
45	Worsening Endothelial Function with Efavirenz Compared to Protease Inhibitors: A 12-Month Prospective Study. PLoS ONE, 2012, 7, e45716.	1.1	37
46	Evaluation of Vitamin D Levels Among HIV-Infected Patients in New York City. AIDS Research and Human Retroviruses, 2012, 28, 235-241.	0.5	45
47	Antiretroviral Treatment of Adult HIV Infection. JAMA - Journal of the American Medical Association, 2012, 308, 387-402.	3.8	1,239
48	Therapeutic Options for Low Bone Mineral Density in HIV-Infected Subjects. Current HIV/AIDS Reports, 2012, 9, 148-159.	1.1	8
49	Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study. BMC Infectious Diseases, 2013, 13, 293.	1.3	18
50	HIV and Osteoporosis. , 2013, , 1305-1329.		1
51	A potential influence of vitamin D on HIV infection and bone disease in HIV-positive patients. HIV and AIDS Review, 2013, 12, 83-88.	0.1	1
53	Cross-Sectional Study of Vitamin D Levels, Immunologic and Virologic Outcomes in HIV-Infected Adults. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1726-1733.	1.8	24
54	Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy. HIV Medicine, 2013, 14, 556-562.	1.0	18
55	Metabolic complications and treatment of perinatally HIVâ€infected children and adolescents. Journal of the International AIDS Society, 2013, 16, 18600.	1.2	81

#	Article	IF	Citations
56	The Relationship Between Vitamin D Status and HIV-related Complications in HIV-infected Children and Young Adults. Pediatric Infectious Disease Journal, 2013, 32, 1224-1229.	1.1	17
57	Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans. Clinical Infectious Diseases, 2013, 56, 1498-1504.	2.9	93
58	In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. American Journal of Clinical Nutrition, 2013, 98, 423-429.	2,2	6
59	Bone Health and Human Immunodeficiency Virus Infection. Pharmacotherapy, 2013, 33, 665-682.	1.2	32
60	Short Communication: High Prevalence of Vitamin D Deficiency in HIV-Infected and HIV-Uninfected Pregnant Women. AIDS Research and Human Retroviruses, 2013, 29, 1224-1228.	0.5	8
61	Serum 25-Hydroxyvitamin D Levels and C-Reactive Protein in Persons with Human Immunodeficiency Virus Infection. AIDS Research and Human Retroviruses, 2013, 29, 528-534.	0.5	41
62	Effects of Switching From Efavirenz to Raltegravir on Endothelial Function, Bone Mineral Metabolism, Inflammation, and Renal Function. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 279-283.	0.9	37
63	Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings. PLoS ONE, 2014, 9, e95164.	1.1	28
64	Outcomes in Older Versus Younger Patients Over 96 Weeks in HIV-1– Infected Patients Treated with Rilpivirine or Efavirenz in ECHO and THRIVE. Current HIV Research, 2014, 11, 570-575.	0.2	9
65	Vitamin D insufficiency and subclinical atherosclerosis in nonâ€diabetic males living with HIV. Journal of the International AIDS Society, 2014, 17, 18945.	1.2	15
66	Different strategies of 250H vitamin D supplementation in HIV-positive subjects. International Journal of STD and AIDS, 2014, 25, 785-792.	0.5	10
67	Determination of optimal vitamin <scp>D₃</scp> dosing regimens in <scp>HIV</scp> â€infected paediatric patients using a population pharmacokinetic approach. British Journal of Clinical Pharmacology, 2014, 78, 1113-1121.	1.1	5
68	LL-37 Concentrations and the Relationship to Vitamin D, Immune Status, and Inflammation in HIV-Infected Children and Young Adults. AIDS Research and Human Retroviruses, 2014, 30, 670-676.	0.5	16
69	Anti-Inflammatory and Antimicrobial Actions of Vitamin D in Combating TB/HIV. Scientifica, 2014, 2014, 1-13.	0.6	50
70	Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons. Journal of Infectious Diseases, 2014, 210, 234-243.	1.9	42
71	Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers. Current Therapeutic Research, 2014, 76, 64-69.	0.5	11
72	Vitamin D and Calcium Abnormalities in the HIV-Infected Population. Endocrinology and Metabolism Clinics of North America, 2014, 43, 743-767.	1.2	8
73	Prevalence of vitamin D deficiency in HIV-positive, antiretroviral treatment-na \tilde{A} -ve patients in a single centre study. International Journal of STD and AIDS, 2014, 25, 488-492.	0.5	11

#	Article	IF	Citations
74	Role of vitamin D in acquired immune and autoimmune diseases. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 232-247.	2.7	48
75	25-Hydroxyvitamin D Insufficiency and Deficiency is Associated With HIV Disease Progression and Virological Failure Post-Antiretroviral Therapy Initiation in Diverse Multinational Settings. Journal of Infectious Diseases, 2014, 210, 244-253.	1.9	46
76	Bone Alterations Associated with HIV. Current HIV/AIDS Reports, 2014, 11, 233-240.	1.1	17
77	Vitamin D Deficiency and Altered Bone Mineral Metabolism in HIV-infected Individuals. Current HIV/AIDS Reports, 2014, 11, 263-270.	1.1	15
78	Factors associated with vitamin D deficiency in a population of 2044 HIV-infected patients. Clinical Nutrition, 2014, 33, 274-279.	2.3	28
79	Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo). Antiviral Therapy, 2014, 19, 191-200.	0.6	37
80	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. Antiviral Therapy, 2015, 20, 261-269.	0.6	5
81	Success of Standard Dose Vitamin D Supplementation in Treated Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases, 2015, 2, ofv068.	0.4	9
82	Comparison of two different strategies of treatment with zoledronate in <scp>HIV</scp> â€infected patients with low bone mineral density: single dose versus two doses in 2 years. HIV Medicine, 2015, 16, 441-448.	1.0	15
83	Bone loss in HIV. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 446-451.	1.2	56
84	Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans. PLoS ONE, 2015, 10, e0144286.	1.1	36
85	Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder. BioMed Research International, 2015, 2015, 1-18.	0.9	81
86	Vitamin D and HIV Infection., 2015, , 157-173.		1
87	Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation. Annals of Internal Medicine, 2015, 162, 815-824.	2.0	100
88	Micronutrients in HIV Infection Without HAART. , 2015, , 271-294.		0
89	Effect of a monthly dose of calcidiol in improving vitamin D deficiency and secondary hyperparathyroidism in HIV-infected patients. Endocrine, 2015, 49, 528-537.	1.1	17
90	No Benefit of Standard Vitamin D/Calcium Supplementation in HIV-infected Individuals. Journal of Infectious Disease and Therapy, $2016, 4, .$	0.1	0
91	Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. AIDS Research and Treatment, 2016, 2016, 1-8.	0.3	9

#	Article	IF	CITATIONS
92	Vitamin D and bone loss in HIV. Current Opinion in HIV and AIDS, 2016, 11, 277-284.	1.5	26
93	Bone health and HIV in resource-limited settings. Current Opinion in HIV and AIDS, 2016, 11, 306-325.	1.5	23
94	The Association of Gender, Age, Efavirenz Use, and Hypovitaminosis D Among HIV-Infected Adults Living in the Tropics. AIDS Research and Human Retroviruses, 2016, 32, 317-324.	0.5	14
95	Effects of Osteoporosisâ€Inducing Drugs on Vitamin Dâ€Related Gene Transcription and Mineralization in <scp>MG</scp> â€63 and Saosâ€2 Cells. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 436-442.	1.2	12
96	Protecting bone in long-term HIV positive patients receiving antiretrovirals. Expert Review of Anti-Infective Therapy, 2016, 14, 587-599.	2.0	4
97	<scp>HIV</scp> infection and bone disease. Journal of Internal Medicine, 2016, 280, 350-358.	2.7	60
98	Change in serum 25-hydroxyvitamin D with antiretroviral treatment initiation and nutritional intervention in HIV-positive adults. British Journal of Nutrition, 2016, 116, 1720-1727.	1.2	1
99	Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency. Medicine (United States), 2016, 95, e4631.	0.4	18
100	Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. Open Forum Infectious Diseases, 2016, 3, ofw097.	0.4	37
101	Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV. Aids, 2016, 30, 1935-1942.	1.0	20
102	An oral high dose of cholecalciferol restores vitamin D status in deficient postmenopausal HIV-1-infected women independently of protease inhibitors therapy: a pilot study. Endocrine, 2016, 53, 299-304.	1.1	9
103	Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth. Journal of Steroid Biochemistry and Molecular Biology, 2017, 168, 38-48.	1.2	6
104	Changes in bone turnover markers with HIV seroconversion and ART initiation. Journal of Antimicrobial Chemotherapy, 2017, 72, 1456-1461.	1.3	12
105	Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. Journal of Antimicrobial Chemotherapy, 2017, 72, 2042-2048.	1.3	5
106	Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects. European Journal of Pharmacology, 2017, 812, 163-173.	1.7	37
107	Associations of Low Vitamin D and Elevated Parathyroid Hormone Concentrations With Bone Mineral Density in Perinatally HIV-Infected Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 33-42.	0.9	10
108	Counter-intuitive plasma vitamin D and zinc status in HIV-1-infected adults with persistent low-level viraemia after treatment initiation: a pilot case–control study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2085-2092.	1.3	2
109	Vitamin D Status in Children Living with HIV on Highly Active Antiretroviral Therapy. Current Tropical Medicine Reports, 2017, 4, 158-165.	1.6	0

#	ARTICLE	IF	CITATIONS
110	Vitamin D Deficiency and Metabolism in HIV-Infected and HIV-Uninfected Men in the Multicenter AIDS Cohort Study. AIDS Research and Human Retroviruses, 2017, 33, 261-270.	0.5	9
111	Vitamin D supplementation, bone turnover, and inflammation in HIV-infected patients. Médecine Et Maladies Infectieuses, 2018, 48, 449-456.	5.1	8
112	The impact of vitamin D supplementation on musculoskeletal health outcomes in children, adolescents, and young adults living with HIV: A systematic review. PLoS ONE, 2018, 13, e0207022.	1.1	8
113	Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?. HIV Clinical Trials, 2018, 19, 188-196.	2.0	3
115	The Hidden Burden of Fractures in People Living With HIV. JBMR Plus, 2018, 2, 247-256.	1.3	29
116	Drug and Hormone Effects on Vitamin D Metabolism. , 2018, , 331-374.		3
117	Serum Vitamin D is Differentially Associated with Socioemotional Adjustment in Early School-Aged Ugandan Children According to Perinatal HIV Status and In Utero/Peripartum Antiretroviral Exposure History. Nutrients, 2019, 11, 1570.	1.7	6
118	VDR polymorphisms influence immunological response in HIV-1+ individuals undergoing antiretroviral therapy. Genetics and Molecular Biology, 2019, 42, 351-356.	0.6	2
119	Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine – results from a German cohort study. International Journal of STD and AIDS, 2019, 30, 447-452.	0.5	1
120	A Randomized Placebo-Controlled Trial of Low-Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 342-349.	0.9	11
121	Relationship Between Vertebral Fractures, Bone Mineral Density, and Osteometabolic Profile in HIV and Hepatitis B and C-Infected Patients Treated With ART. Frontiers in Endocrinology, 2019, 10, 302.	1.5	6
122	Adherence to risk management guidelines for drugs which cause vitamin D deficiency – big data from the Swedish health system. Drug, Healthcare and Patient Safety, 2019, Volume 11, 19-28.	1.0	3
123	Markers of Bone Mineral Metabolism and Cardiac Structure and Function in Perinatally HIV-Infected and HIV-Exposed but Uninfected Children and Adolescents. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 238-246.	0.9	3
124	Antiretroviral-naìve HIV-infected patients had lower bone formation markers than HIV-uninfected adults. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 984-993.	0.6	4
125	Vitamin D Status Modulates Inflammatory Response in HIV+ Subjects: Evidence for Involvement of Autophagy and TG2 Expression in PBMC. International Journal of Molecular Sciences, 2020, 21, 7558.	1.8	8
126	Risk Factors of Hypovitaminosis D in HIV-Infected Patients on Suppressive Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2020, 36, 676-680.	0.5	2
127	People living with HIV and fracture risk. Osteoporosis International, 2020, 31, 1633-1644.	1.3	25
128	Osteopenia and osteoporosis among treatment-experienced people living with HIV. Brazilian Journal of Infectious Diseases, 2020, 24, 288-295.	0.3	4

#	Article	IF	CITATIONS
129	Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. Current HIV Research, 2021, 19, 61-72.	0.2	3
130	Laboratory assessment of acquired immunodeficiency syndrome endocrinopathies., 2021,, 477-496.		0
131	Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA. Journal of Applied Biomedicine, 2021, 19, 73-82.	0.6	2
132	Prevalence and association with birth outcomes of low vitamin D levels among pregnant women living with HIV. Aids, 2021, 35, 1491-1496.	1.0	2
133	Vitamin D status and associated factors among HIV-infected children and adolescents on antiretroviral therapy in Kampala, Uganda. PLoS ONE, 2021, 16, e0253689.	1.1	4
134	Human immunodeficiency virus and osteoporosis. , 2021, , 1217-1238.		0
135	Vitamin D and Infectious Diseases. Contemporary Endocrinology, 2018, , 57-75.	0.3	2
136	The Role of Vitamin D in Human Immunodeficiency Virus Infection. , 2015, , 175-188.		1
137	The role of micronutrients in the diet of HIV-1-infected individuals. Frontiers in Bioscience - Elite, 2012, E4, 2442-2456.	0.9	21
138	Human Immunodeficiency Virus Infection and the Endocrine System. Endocrinology and Metabolism, 2019, 34, 95.	1.3	19
139	HIV/AIDS and Bone Health: The Role of Nutrition. , 2015, , 645-657.		0
140	Heterogeneity in Nutritional and Lipid Profiles in Children and Adolescents with Human Immunodeficiency Virus Treated with Highly Active Antiretroviral Therapy. , 2015, , 401-418.		0
141	latrogenic Osteoporosis. Mìžnarodnij EndokrinologìÄnij Žurnal, 2016, .	0.1	0
142	Bone Biomarkers in HIV. Exposure and Health, 2016, , 1-27.	2.8	0
143	HIV Associated Non-AIDS Conditions in Patients Aging with HIV. , 2016, , 19-52.		1
144	Bone Biomarkers in HIV. Biomarkers in Disease, 2017, , 755-781.	0.0	O
145	Low Vitamin D is associated with Coronary Atherosclerosis in Women with HIV. Antiviral Therapy, 2019, 24, 505-512.	0.6	5
146	VITAMIN D AND HIV INFECTION: THE CORRELATION & NEED FOR EVALUATION. International Journal of Research -GRANTHAALAYAH, 2019, 7, 68-82.	0.1	O

#	Article	IF	CITATIONS
147	HIV Infection, HIV Therapy, and Bone Health., 2020, , 146-155.		0
148	Associação entre Hipovitaminose D e SÃndrome da Imunodeficiência Adquirida. Research, Society and Development, 2020, 9, e85942679.	0.0	0
149	Complications of HIV disease and antiretroviral treatment. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2010, 18, 57-65.	2.9	2
150	Vitamin D, bone, and HIV infection. Topics in Antiviral Medicine, 2012, 20, 168-72.	0.1	9
152	Challenges in the management of osteoporosis and vitamin D deficiency in HIV infection. Topics in Antiviral Medicine, 2013, 21, 115-8.	0.1	10
153	A Study of Vitamin D Levels in HIV Seropositive Patients. Journal of Evolution of Medical and Dental Sciences, 2022, 11, 66-71.	0.1	O
154	Vitamin D and Calcium Supplementation Reverses Tenofovir-Caused Bone Mineral Density Loss in People Taking ART or PrEP: A Systematic Review and Meta-Analysis. Frontiers in Nutrition, 2022, 9, 749948.	1.6	3
155	Low bone mass and vitamin D in Brazilian people living with HIV under antiretroviral therapy. Archives of Osteoporosis, 2022, 17, 40.	1.0	1
157	Cholecalciferol Supplementation Does Not Affect the Risk of HIV Progression, Viral Suppression, Comorbidities, Weight Loss, and Depression Among Tanzanian Adults Initiating Antiretroviral Therapy: Secondary Outcomes of a Randomized Trial. Journal of Nutrition, 2022, , .	1.3	0
158	A Systematic Review and Meta-Analysis of Randomized Controlled Trials of the Effects of Vitamin D Supplementation on Children and Young Adults with HIV Infection. Journal of Nutrition, 2023, 153, 138-147.	1.3	3